PHASE II TRIAL OF ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS: ADDITIVE ANALYSIS OF PHARMACOKINETICS OF ERLOTINIB

¹Respiratory Medicine, Japanese Red-Cross Nagasaki Genbaku Hospital, Japan, ²Second Department of Internal Medicine, Nagasaki University School of Medicine, Japan, and ³Department of Drug Metabolism and Disposition, Meiji Pharmaceutical University, Japan